ID: ALA144115

Max Phase: Preclinical

Molecular Formula: C28H30N8O3

Molecular Weight: 526.60

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cccc2nc3cccc(C(=O)NCCCN(C)CCCNc4n[n+]([O-])c5ccccc5[n+]4[O-])c3nc12

Standard InChI:  InChI=1S/C28H30N8O3/c1-19-9-5-11-21-25(19)32-26-20(10-6-12-22(26)31-21)27(37)29-15-7-17-34(2)18-8-16-30-28-33-36(39)24-14-4-3-13-23(24)35(28)38/h3-6,9-14H,7-8,15-18H2,1-2H3,(H,29,37)(H,30,33)

Standard InChI Key:  SKWKMSWTRWUAGT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 526.60

Molecular Weight (Monoisotopic): 526.2441

AlogP: 2.46

#Rotatable Bonds: 10

Polar Surface Area: 136.92

Molecular Species: BASE

HBA: 8

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 7.50

CX Basic pKa: 9.41

CX LogP: 2.63

CX LogD: 0.62

Aromatic Rings: 5

Heavy Atoms: 39

QED Weighted: 0.12

Np Likeness Score: -0.71

References

1. Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA..  (2004)  DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.,  47  (2): [PMID:14711317] [10.1021/jm030399c]

2. Cascioferro S, Parrino B, Spanò V, Carbone A, Montalbano A, Barraja P, Diana P, Cirrincione G..  (2017)  An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds.,  142  [PMID:28851503] [10.1016/j.ejmech.2017.08.009]

Source

Source(1):

• Scientific Literature